Printer Friendly

Allergy drug prevents heart transplant complication in mice.

Tranilast, a drug widely used in the treatment of allergic diseases, inhibits the proliferation of cells within coronary blood vessels that can occur after cardiac transplantation, according to a study conducted at Tokyo Medical and Dental University in Japan.

Tranilast treatment in mice started 3 days prior to heart transplantation and continued for 28 days thereafter was linked to a marked reduction in blood vessel occlusion and had no significant effects on allograft rejection, the researchers reported. Since cardiac allograft vasculopathy (CAV), characterized by accelerated thickening of the inner lining of the coronary arteries, remains a major cause of late death in cardiac transplant recipients, tranilast may have the potential to enhance allograft survival by preventing CAV, they concluded. (Arteriosclerosis, Thrombosis, and Vascular Biology 2001;21:1172-1178.)
COPYRIGHT 2001 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Allergy drug prevents heart transplant complication in mice.
Publication:Transplant News
Geographic Code:9JAPA
Date:Aug 17, 2001
Previous Article:Rare domino transplant gives man a new liver as his goes to another.
Next Article:T cell injection triggers islet cell transplant acceptance.

Related Articles
New drug that reduces scarring could reduce need for a heart transplant.
Adult stem cells source of revolutionary new treatment for heart attack patients, three new studies find.
New methods for improving mismatched BMT success rates.
Bacteria offer drug for organ recipients. (Biomedicine).
Justifiable transplantation.
NIAID launches 3-site consortium to study improving long term quality of life for transplant recipients.
Carbon monoxide may save lives of organ transplant recipients, study finds.
CEL-SCI receives United States patent for use of peptide vaccine technology for autoimmune conditions and allergies.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters